MetaVia DA-1726 48 mg Phase 1 Detailed Numbers at EASL 2026: 9.1% Mean Weight Loss and 9.8 cm Waist Reduction at Day 54 With FibroScan Liver Improvements
MetaVia's higher-dose Phase 1 readout for DA-1726 at EASL 2026 produced specific efficacy numbers: the 48 mg cohort in obese but otherwise healthy adults achieved 9.1% mean body-weight reduction and a 9.8 cm waist-circumference reduction at Day 54, with exploratory FibroScan liver improvements and no serious adverse events. DA-1726 is a once-weekly subcutaneous oxyntomodulin analog acting as a 3:1 ratio GLP-1/glucagon dual receptor agonist for obesity and MASH. The 9.1% weight loss in roughly eight weeks is a fast trajectory for an early-phase obesity peptide and supports MetaVia's case heading into the 16-week Phase 1 Part 3 titration study reading out Q4 2026. The waist reduction (a glucagon-receptor-driven visceral-fat signal) and the FibroScan liver improvements position DA-1726 in the dual obesity-and-MASH lane alongside survodutide and pemvidutide. MetaVia's three ADA 2026 late-breaking abstracts (June 7 New Orleans) extend the DA-1726 and vanoglipel data sets.